The inaugural Biomolecular Condensates Summit is uniting biopharma and academia to address the knowledge gap in understanding the role of biomolecular condensates in disease biology and progression and to advance biomolecular condensates as viable therapeutic targets. Hear from pioneering leaders like Merck, Biogen and Amgen across 3 days of in-depth case studies, interactive panel discussions, dedicated Q+A time and highly appraised networking opportunities to meet and learn from those pioneering this emerging field. If you are dedicated to further understanding the role of biomolecular condensates in disease biology and progression, developing the appropriate tools to study condensate materials and functions, or therapeutically targeting biomolecular condensates then this is THE place to be! Join the community and establish yourself as a pioneer in this emerging field! https://biomolecularcondensates-summit.com/ April 21-23, 2020 Contact:This email address is being protected from spambots. You need JavaScript enabled to view it.+1 617 455 4188 URLs:Brochure: https://go.evvnt.com/581076-0?pid=5569Tickets: https://go.evvnt.com/581076-1?pid=5569 Prices:Conference Only: USD 2299.0,Conference + 1 Workshop (A or B): USD 2698.0,Conference + 2 Workshops (A and B): USD 3097.0,Workshops (Individual): USD 499.0 Speakers: Sophie Parmentier-Batteur, Director Neurodegenerative Diseases Discovery, Merck, Clifford Brangwynne, Professor of Chemical and Biological Engineering, Princeton / HHMI, David McSwiggen, Scientist, Eikon Therapeutics, Ben Wolozin, CSO, Aquinnah, Haruki Hasegawa, Principal Scientist, Amgen, Jason Imbriglio, Director Chemical Biology, Merck, Brandon Maziuk, Scientist, Biogen, Jonathan Behr, Partner, Dementia Discovery Fund Date and Time: On Tuesday April 21, 2020 at 8:00 am (ends Thursday April 23, 2020 at 5:00 pm) Venue Details: The Colonnade Hotel, 120 Huntington Avenue, Boston, Massachusetts, 02116, United States